KR20010106511A - Perfusate preperation for ophthalmic operation - Google Patents

Abstract

The present invention relates to a one-component intraocular perfusion solution with excellent biosafety and excellent protection of intraocular tissues and endothelial cells during and after surgery in eye surgery for cataract, glaucoma or intraocular lens implantation. This formulation comprises at least one compound selected from the group consisting of D-3-hydroxybutyl acid and its water-soluble salts, at least one compound selected from the group consisting of water-soluble bicarbonates, phosphoric acid and water-soluble phosphates, water-soluble calcium salts and water-soluble magnesium It becomes the aqueous solution containing a salt.

Description

Perfusion solution for ocular surgery {PERFUSATE PREPERATION FOR OPHTHALMIC OPERATION}

In recent years, the development of ophthalmic surgery methods such as cataract surgery, intraocular lens implant surgery and glaucoma surgery has made remarkable progress. In order to perform the above operation safely and effectively, the perfusion fluid used as a surgical aid plays an important role. For example, at the start of cataract surgery, the incision of the periphery of the cornea by the scalpel at the beginning of the operation prevents the release of water from the anterior chamber. Injecting viscoelastic materials is inevitable. In addition, if perfusion fluid is present in the eye during crushing and extraction of turbid crystalline lens, suction removal of crushed material can be performed smoothly. Perfusate is also used to prevent drying of the cornea surface during surgery.

Precautions under the preparation to achieve the purpose of the use of such perfusate: 1) the penetration pressure and pH should be physiologically harmonized with intraocular tissues and endothelial cells, 2) inorganic salts, energy sources and cell reactivators Add essential compounds of the waterproofing component, 3) biologically safe, 4) long-term storage at room temperature as a formulation.

Currently, as a perfusion solution for ocular surgery commercially available in Japan, there are products in which oxyglutathione is blended as a cell activator, and a product having a buffer system based on bicarbonate ions has been put into practical use. However, since they are two-component preparations to be mixed in use or do not contain ingredients effective for the protection of the corneal endothelium, there are many problems to be solved in terms of stability, simplicity in use, and efficacy in preparation. have.

In addition, eye perfusion solution formulations based on 3-hydroxybutyl acid as an energy source are disclosed in US Pat. Nos. 5,116,868 and 5,298,487. However, this patent specification does not contain the bicarbonate ions necessary to maintain the function of the corneal endothelium. For this reason, if bicarbonate ions are present in the formulation, the pH of the formulation is unstable due to CO ₂ partial pressure, and the 3-hydroxybutyl acid generates CO ₂ by metabolism, and this CO ₂ changes to bicarbonate ions. Since bicarbonate ions are supplied automatically, it is described that there is no need to blend the bicarbonate ions into the preparation in advance. In addition, the preparation contains sodium acetate which is not present in the waterproofing component of humans.

D-3-hydroxybutyl acid or its salts, which are used as active ingredients in the present invention, are known as biological components of humans and most other mammals, are biosynthesized during the oxidation of fatty acids in the liver, including the cornea by the blood. It is transported to peripheral tissues outside the liver and used as an efficient energy source (see LEHNINGER Neochemistry, 2nd edition, p625, 1993 and NATURE, No.4841, p597, 1962). It is also known that this substance is extremely useful for corneal tissue as an energy production substrate rather than glucose (see TRANSPLANTATI0N, 57, p1778 to 1785, 1994).

D-3-hydroxybutyl acid or its salts are oxidized in the TCA cycles of these tissues to produce APT and finally to gas and water (see NATURE, No.4841, p597, 1962).

The application of D-3-hydroxybutyl acid and its salts to pharmaceuticals has been reported as an infusion formulation component for nutritional supplementation to patients with hyperproteinization or invasion of the body (Japanese Patent Application Laid-Open No. 2-191212). Publication).

Ophthalmic Clinic Review Vol. 92, No. 7 (1998), pp. 902 to 905, describes the effect of intraocular perfusion solution containing β-hydroxybutylate on the retina. As a result of the investigation by ERG, it is disclosed that the retinal function is maintained at the same or higher level than that of the commercially available BSS PLUS. However, in this report, there is no disclosure of the D-form of β-hydroxybutylate, but only the effect on the retina is disclosed.

In addition, the effects of intraocular perfusion fluid on the retina of the new prescription containing D-sodium β-hydroxybutylate were included in the program and lecture Abstract Collection 201, held at the 36th General Meeting of the Japanese Retinal Vegetative Society on July 24 to 26, 1997. As a result of examining ERG using the extracted rabbit retina, it is disclosed that ERG of retinal in vitro samples can be maintained at or equal to BSS PLUS.

However, this report does not disclose the detailed composition of the intraocular perfusion solution, only the effect on the retina.

Disclosure of the Invention

Disclosure of Invention It is an object of the present invention to provide a one-part intraocular perfusion solution with excellent protection of eye tissues and endothelial cells and high biosafety during and after surgery in cataracts, glaucoma or intraocular lens implantation. .

Another object of the present invention is to add an inorganic ion, an energy source, a tonicity adjustment agent, a buffer, a bicarbonate ion and a stabilizer, and the like to add a more formulationally stable intraocular perfusion liquid formulation in addition to the above excellent properties. To provide.

Still other objects and advantages of the present invention will become apparent from the following description.

According to the present invention, the above objects and advantages of the present invention

(1) at least one compound selected from the group consisting of D-3-hydroxybutyl acid and its water-soluble salts, as D-3-hydroxybutyl acid anion, at least 0.1 mM and less than 500 mM,

(2) 0.1 to more than 100 mM of water-soluble bicarbonate as a medium carbon ion;

(3) at least one compound selected from the group consisting of phosphoric acid and water-soluble phosphate salts as at least 0.1 mM and less than 50 mM,

(4) 0.01 to more than 50 mM of water-soluble calcium salt as calcium ion and

(5) 0.01mM or more and less than 50mM of water-soluble magnesium salts as magnesium ions

It is achieved by the one-component perfusion formulation for cataract surgery, glaucoma surgery or intraocular lens transplant surgery, characterized in that the aqueous solution containing a.

The present invention relates to a perfusion formulation for ocular surgery for use in cataract surgery, intraocular lens implant surgery, or glaucoma surgery. More particularly, the present invention relates to a perfusion preparation for ocular surgery that is well suited for the protection of intraocular tissue, the aspiration removal of surgical residues in the eye, and the prevention of drying of the corneal epithelium and conjunctiva in order to perform the surgery safely and effectively.

1 shows a comparison of the cell reactivation effect of the optical isomer of 3-hydroxybutyl acid (3-HBA).

Figure 2 shows the protective action (in vitro experiments) on the cornea of the solution of the present invention and the comparative solution.

Figure 3 shows the amount of change over time with respect to the corneal thickness of each solution.

Figure 4 shows the recovery effect on cultured bovine corneal endothelial cells that caused the interference of D-3-HBA and oxyglutathione.

Figure 5 shows the amount of change over time for corneal thickness with or without D-3-HBA in the formulation containing bicarbonate.

Figure 6 shows the amount of change over time with respect to the corneal thickness in the presence of D-3-HBA in the formulation containing no bicarbonate.

Detailed description of the invention

Hereinafter, the formulation of the present invention will be described in detail.

Regarding the absolute stereoposition of the C 3 position in the chemical structural formula of 3-hydroxybutyl acid, there are a group of D, D, L and L forms. Among them, D-body is used in the present invention to maximize the effectiveness of the perfusion fluid preparation for ocular surgery. The reason for this is to investigate the difference in activity based on optical isomers regarding the reactivation of corneal endothelial cells, which is one of the methods for evaluating the efficacy of the preparation. This is because, when L is used, it is considered to be affected by the negative effect of L.

D-3-hydroxybutyl acid and its salts are easily synthesized in asymmetric yields by asymmetric hydrogenation of ketone groups of acetic acetate esters as ruthenium-optically active phosphine complexes, followed by alkali hydrolysis of esters. Since this is possible, this compound can be obtained relatively cheaply (refer Unexamined-Japanese-Patent No. 6-99367).

As the water-soluble salt of D-3-hydroxybutyl acid in the present invention, for example, sodium salt, potassium salt, barium salt, magnesium salt, lithium salt, L- lysine salt, L- histidine salt and L- Arginine salts.

D-3-hydroxybutyl acid and these water-soluble salts can be used individually or in combination of 2 or more types.

In the present invention, "water-soluble" refers to a property of dissolving in the formulation of the present invention to the desired concentration required for the formulation.

In the present invention, the concentration of the aqueous solution preparation of D-3-hydroxybutyl acid and / or the water-soluble salt is at least 0.1 mM and less than 500 mM, preferably at least 1 mM and less than 200 mM, more preferably at least 5 mM and less than 100 mM.

In the present invention, the combination of bicarbonate ions has a remarkable effect on the effect of inhibiting corneal swelling, which is one of the important indexes for maintaining corneal function. Actually, the cornea thickness extracted from the rabbit was incubated with the addition or addition of bicarbonate ions, and the change in corneal thickness was measured. As a result, the ion-adding agent (the present invention) restored the state of the cornea to almost normal state. In contrast, in the ion-free formulation, swelling of the cornea was accelerated, and the corneal protection was found to be insufficient. Similarly to in vivo experiments using rabbits, the swelling of the cornea was accelerated in the ion-free formulation while the ion-adding agent (the present invention) restored the cornea to its normal state.

In view of the above, the blend of bicarbonate ions is essential for the present invention formulation of D-3-hydroxybutyl acid blend.

As the water-soluble bicarbonate, for example, sodium bicarbonate and potassium bicarbonate are preferable.

The concentration of the water-soluble bicarbonate is water-soluble bicarbonate ion (HCO ₃ ⁻ ) of 0.1 mM or more and less than 100 mM, preferably 1 mM or more and less than 60 mM, more preferably 10 mM or more and less than 60 mM.

The formulation of the present invention contains phosphate ions. Phosphate ions are derived from phosphoric acid or water soluble phosphates. The phosphate ion is preferably derived from a phosphate buffer consisting of a water-soluble phosphate such as, for example, sodium dihydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, or potassium dihydrogen phosphate. Phosphoric acid-based buffers are present as waterproofing components of humans. The phosphate ion concentration is at least 0.1 mM and less than 50 mM, preferably at least 0.5 mM and less than 30 mM, more preferably at least 1 mM and less than 10 mM.

The formulation of the present invention further contains a calcium salt. The calcium salt may be added to the formulation of the present invention as a salt consisting of the above-mentioned D-3-hydroxybutyl acid ion, bicarbonate ion or phosphate ion and calcium ion, or other water-soluble salt. Examples of such other water-soluble salts include calcium chloride, calcium glycerophosphate and calcium glucurate. Calcium salt can be used 1 type or in combination of 2 or more types.

The concentration of the water-soluble calcium salt is at least 0.01 mM and less than 50 mM, preferably at least 0.1 mM and less than 20 mM, and more preferably at least 0.5 mM and less than 10 mM as calcium ions.

The formulation of the present invention further contains a water-soluble magnesium salt. The magnesium salt may be added to the formulation of the present invention as a salt consisting of the above-mentioned D-3-hydroxybutyl acid ion, bicarbonate ion or phosphate ion and magnesium ion, or other water-soluble salt. As these other water-soluble salts, magnesium chloride and magnesium sulfate are mentioned, for example.

The concentration of the water-soluble magnesium salt is magnesium ion, which is 0.01mM or more and 50mM, preferably 0.1mM or more and less than 20mM, more preferably 0.5mM or more and less than 10mM.

Additives of perfusate formulations in the present invention include inorganic salts present in the aqueous humor of humans, isotonic and buffering agents to balance glucose, penetration pressure and pH with intraocular tissues and endothelial cells as other energy sources, and stabilizers of the formulations. It is preferable to use etc. suitably.

Inorganic salts and isotonic agents used in the present invention include, in addition to the calcium salts and magnesium salts, inorganic salts such as alkali metal salts such as sodium chloride, potassium chloride and the like, and saccharides such as mannitol, sorbitol, xylitol, and dextran. Isotonic agents such as are preferably used.

These may be used alone or in combination of two or more. The concentration of these inorganic salts and tonicity agents is preferably in the range of 0.1 to 1,000 mM. Moreover, it is preferable to maintain the penetration pressure of a formulation in the range of 270-350 m0sm.

As the buffer, in addition to the above water-soluble phosphate, citric acid, citrate, bicarbonate, acetate can be used, and a boric acid-based buffer such as boric acid and sodium borate can also be used. The concentration of the buffer is preferably in the range of 0.1 to 50 mM.

The pH range of the aqueous solution preparation of the present invention is preferably pH 6.8-8.2, and more preferably pH 7.2-8.0, which is necessary for maintaining their function without causing trouble to intraocular tissues and cells. As a result of the functional test and safety test using rabbit eyes, these pH ranges are acceptable as perfusion fluid for ocular surgery.

In the present invention, the main energy source of the perfusate formulation is D-3-hydroxybutyl acid, but glucose may be added as an auxiliary energy source. The concentration of glucose is preferably in the range of 0.1 to 50 mM.

As a stabilizer, water-soluble citrate is used preferably. As water-soluble citrate, citric acid and the sodium and potassium salts of citric acid are preferable, for example. The concentration of citrate ions is preferably in the range of 0.01 to 50 mM, more preferably in the range of 0.1 to 10 mM.

These main components and additives can be dissolved in distilled water one after another, and the pH is adjusted with dilute hydrochloric acid or dilute alkaline liquid, and then all can be kept closed by using a transparent or plastic bottle as a one-part formulation. . The sample stored in this manner for 6 months at 40 ° C and 75% humidity did not change in appearance, penetration pressure, or the like, compared with the start of the test. On the other hand, with regard to pH, when citric acid or its salt is set at a concentration of preferably 0.1 to 1.5 mM, more preferably 0.1 to 10 mM, pH 7.3 to 7.4 of the formulation at the start of the test is 7.4 to 7.8 even at the end of storage. The variation of the pH of the aqueous solution is relatively small, and a relatively stable perfusion liquid formulation is obtained even when bicarbonate ions are present.

Hereinafter, although an Example demonstrates this invention concretely, this invention is not limited to these Examples.

Example 1

Solution No. 1 (Example) and No. 2 (Comparative Example) dissolve a predetermined amount of the components shown in Table 1 in distilled water sequentially from the top, and finally D-3-hydroxybutyrate (hereinafter, D 3-HBA was abbreviated), and the total amount was made into 1 L of aqueous solution, pH was adjusted with dilute hydrochloric acid, and then aseptically filtered to obtain a test perfusion solution. In addition, the component and these density | concentration of commercial item B (comparative liquid 1) and product M (comparative liquid 2) used as a comparative example are shown in Table 1 together.

Table 1

(mM)

Composition Solution No. 1 Solution No. 2 Comparative Example 1 Comparative Example 2 NaCl 100.3 100.0 122.2 112.9 KCl 5.1 - 5.08 4.8 MgCl ₂ 1.0 1.0 0.98 - CaCl ₂ 1.1 2.0 1.05 1.2 K ₂ HPO ₄ - 5.0 - - Na ₂ HPO ₄ 3.0 5.0 3.0 - Sodium citrate 0.34 10.0 - 3.4 NaHCO ₃ 25.0 - 25.0 25.0 Sodium acetate - 20.0 - 4.4 D-3-HBA 20.0 - - - D, L-3-HBA - 10.0 - - Oxyglutathione - - 0.30 - Glucose 5.0 5.5 5.11 8.3

Example 2

The formulation stability test of the solution No. 1 containing the D-3-HBA of Example 1 was done. 500 mL of this preparation was filled into a 600 mL transparent glass container, and it sealed and produced five test liquids. They were stored for 6 months in a thermo-hygrostat with temperature control at 40 ° C. ± 0.5 and humidity control at 75 ± 5% RH. As a result, solution appearance, insoluble foreign material test, and penetration pressure did not change. Regarding the pH of the solution, the pH at the start of storage was 7.3 to 7.4, but since the pH was 7.4 to 7.8 after 6 months of storage, the variation was relatively small, and it was found that the preparation can be stably stored at room temperature for a long time.

Example 3

Isomer of 3-HBA, Form D. In order to show that the D-form of D, L-form and L-form is effective, the cell reactivation effect of each isomer was based on the following MTT assay using cultured keratinocyte endothelial cells (Chem. Pharm. Bu11., 41 1118, 1993).

Incubated with incubated endothelial cells preliminarily cultured with a solution of D-, D-, L-, and L-form D-3-HBAs in 0 (control), 5, and 20 mM concentrations in DULBECCO's MEM salt medium. One (4 × 10 ⁴ ce11 / ml) was injected into a 24we11 collagen coated plate and cultured for 48 hours. After incubation, 50 µl of a cell counting kit was added to each we11, followed by color development. The absorbance at 450 nm was measured using supernatant. The results are shown in FIG.

Regarding the cell reactivation effects of the D, D, L and L bodies, at all concentrations, the cells in the culture with D-3-HBA were the most active and the suitable concentration was 20 mM. Compared with the control group (no addition of HBA), L body did not find significant difference at any concentration, and in D and L body, significant difference with control group was found at 5mM and 20mM.

Example 4

The effect of the protective action on the cornea was compared by in vitro experiments using four types of test perfusion liquids of Solution No. 1, No. 2, Comparative Solution 1 and Comparative Solution 2 of Example 1.

The cornea was removed from the mature rabbit and the cornea was attached to the periphery of the cornea about 20 mm (20 sheets in total, 5 for each of the 4 test solutions), and cultured for 5 hours under 36 ° C in the perfusion solution. The subsequent corneal thickness was measured by an ultrasonic corneal thickness gauge (DGH-500 PACHETTE, manufactured by DGH TECHNOL0GY).

The corneal thickness change amount (= corneal thickness before culture-corneal thickness after 5 hours of culture) after 5 hours of culture of each test solution is shown in FIG. 2.

Solution No. 1, in which D-3-HBA and bicarbonate ions were combined, showed a remarkable effect on cornea protection as compared to Solution No. 2, which did not contain bicarbonate ions, and also with Comparative Solution 1 and Comparative Solution 2 of commercially available products. In comparison, an inhibitory effect of at least an equivalent level was shown for corneal swelling.

Example 5

Example 1 Experimental perfusion liquid No. 1, No. 2, Comparative liquid 1 and Comparative liquid 2 were used in the same manner, and used for intraperfusion perfusion of Dutch rabbits (male, body weight: 1.9 to 2.9 kg). The effect on corneal thickness by in vivo experiments was investigated.

After general anesthesia by intramuscular injection of each individual of rabbits with xyladine hydrochloride and getamine, hydrochloric incision was made in the corneal ring of the left and right eyes of each individual by 3.2 mm width and the needle tip was rounded. The cut 18G injection needle was inserted inwardly from the incision, and four test perfusion liquids were perfused for 120 minutes at a flow rate of 10 ml / min, respectively. The amount of change in corneal thickness of each test solution was measured using the above-mentioned ultrasonic corneal thickness meter under the topical anesthesia of 0.4% oxyprocaine up to 120 minutes before and 30 minutes after the start of perfusion. The amount of change over time of each corneal thickness is shown in FIG.

As a result, similarly to the results of in vitro experiments of Example 4, Figure 3 shows that solution No. 1 containing D-3-HBA and bicarbonate ion was obtained by solution No. 2, comparative solution 1 and comparative solution 2 without bicarbonate ion. Compared with the perfusion solution, the change in corneal thickness is small, indicating that the perfusion solution preparation has excellent corneal protective effect.

Example 6

The barrier function recovery experiment of cultured keratin endothelial cells subjected to ultrasound damage was performed as an invasive model assuming the ultrasonic emulsification aspiration used as a surgical method during cataract surgery.

Using incinerated endothelial cells subjected to ultrasonic interference, the barrier functional recovery effects of D-3-HBA and oxy glutathione were tested as follows.

The sonication of 92 W / cm <^2> was irradiated 3 times at 0.1 second intervals, and the obstacle was added. Cultured incubated endothelial cells on the filter were cultured in DULBECCO's MEM medium (10% fetal calf serum added) containing 20 mM D-3-HBA or 0.3 mM oxyglutathione, and the electrical resistance over time of this endothelial cell layer. The degree of recovery of the barrier function was measured using the change in value, and the results are shown in FIG. 4.

The electric resistance value of mono1ayer in the medium containing D-3-HBA showed a value closer to the resistance value before the ultrasonic irradiation at any observation time, compared to the oxyglutathione-containing medium and its MEM medium, and the early recovery of the barrier function. Effect.

Example 7

Solution No. 1 (Example), Solution No. 3, Solution No. 4, Solution No. 5 (Comparative Example) dissolved a predetermined amount of the components shown in Table 2, and finally dissolved D-3-HBA. The total amount was made into 1 liter of aqueous solution, pH was adjusted with dilute hydrochloric acid, and then aseptically treated to obtain a test perfusion liquid.

TABLE 2

(mM)

Bicarbonate oil Bicarbonate Solution No. One 3 4 5 D-3-HBA 20 0 0 20 NaCl 100.3 122.0 145.4 123.7 KCl 5.1 5.1 5.1 5.1 Na ₂ HPO ₄ 3.0 3.0 3.0 3.0 Sodium citrate 0.34 0.34 0.34 0.34 MgCl ₂ 1.0 1.0 1.0 1.0 CaCl ₂ 1.1 1.1 1.1 1.1 NaHCO ₃ 25.0 25.0 - - Glucose 5.0 5.0 5.0 5.0

Dutch rabbit (male, body weight; 1.9-2.9 kg) was used in the experiment. For rabbits, ophthalmic scalpels are used in the corneal rings after general anesthesia by intramuscular injection of xyladine hydrochloride (Celactal, Bayer Pharmaceutical Co., Ltd.) and chemistry hydrochloride (Ketral, Sankyo Co., Ltd.). A 3.2 mm wide incision was opened, and an 18G needle cut from the incision was inserted into the anterior portion, and the perfusion liquid was perfused for 90 minutes at a flow rate of 10 ml / min. After the end of perfusion, the incision was closed with a threaded suture needle. The corneal thickness was measured before and after perfusion (30 minute intervals) by the ultrasonic corneal thickness meter used in Example 4.

By combining D-3-HBA and bicarbonate ions in the intraocular perfusion solution, there was an effect of keeping the corneal thickness change of D-3-HBA small (FIG. 5). On the other hand, there was no effect of keeping the corneal thickness change of D-3-HBA small by the formulation which does not mix bicarbonate ion in intraocular perfusion liquid (FIG. 6).

As described above, according to the present invention, by further combining D-3-hydroxybutyl acid and / or its salts, bicarbonate ions, phosphate ions, calcium ions, magnesium ions, and optionally citric acid ions, Surgical perfusion solution with high safety and excellent protective effect of eye tissues including corneal endothelial cells and recovery from physical invasion, and stable eye perfusion by adding inorganic salt, isotonic agent, glucose, buffer and stabilizer Liquid formulations could be prepared.

Claims (8)

(1) at least one compound selected from the group consisting of D-3-hydroxybutyl acid and its water-soluble salts is 0.1 mM or more but less than 500 mM as D-3-hydroxybutyl acid anion; (2) 0.1mM or more and less than 100mM as water soluble bicarbonate as bicarbonate ion (3) at least one compound selected from the group consisting of phosphoric acid and water-soluble phosphate is 0.1mM or more and less than 50mM as phosphate (4) 0.01 to more than 50 mM of water-soluble calcium salt as calcium ion and (5) 0.01mM or more and less than 50mM of water-soluble magnesium salts as magnesium ions A one-component perfusion solution for cataract surgery, glaucoma surgery or intraocular lens transplant surgery, characterized in that it comprises an aqueous solution containing a solution. The method of claim 1, The water-soluble salts of D-3-hydroxybutyl acid are sodium salts, potassium salts, barium salts, magnesium salts, lithium salts, L-lysine salts, L-histidine salts and L-arginine salts of D-3-hydroxybutyl acid. A one-component perfusion formulation for cataract surgery, glaucoma surgery or intraocular lens transplant surgery, characterized in that it is selected from the group consisting of: The method of claim 1, A one-component perfusion solution for cataract surgery, glaucoma surgery or intraocular lens transplant surgery, characterized in that the water-soluble bicarbonate is sodium bicarbonate or potassium bicarbonate. The method of claim 1, 1-component perfusion solution for cataract surgery, glaucoma surgery or intraocular lens implantation, characterized in that the water-soluble phosphate is selected from the group consisting of sodium dihydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate and dihydrogen phosphate dipotassium. Formulation. The method of claim 1, A one-component perfusion solution for cataract surgery, glaucoma surgery or intraocular lens transplant surgery, characterized in that the water-soluble calcium salt is selected from the group consisting of calcium chloride, calcium glycerophosphate and calcium gluguronate. The method of claim 1, A one-component perfusion solution for cataract surgery, glaucoma surgery or intraocular lens implant surgery, characterized in that the water-soluble magnesium salt is magnesium chloride or magnesium sulfate. The method of claim 1, A one-component perfusion formulation for cataract surgery, glaucoma surgery or intraocular lens transplant surgery, further comprising water-soluble citric acid and / or salts thereof. The method of claim 7, wherein A one-component perfusion solution for cataract surgery, glaucoma surgery or intraocular lens implant surgery, characterized in that the water-soluble citrate is sodium citrate or potassium citrate.